中核的臨床分子診断の中核市場- 世界の産業規模、シェア、動向、機会、予測、セグメント、製品タイプ別、技術別、用途別、エンドユーザー別、地域別、競合、2020年～2030年

中核的臨床分子診断の中核の世界市場規模は、2024年に64億8,000万米ドルとなり、2030年までのCAGRは9.89％で、予測期間には114億3,000万米ドルに達すると予測されています。

世界の臨床分子診断市場は、特にがん、感染症、遺伝性疾患など様々な疾患の正確かつ早期発見に対する需要の高まりにより、著しい成長を遂げています。ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）、蛍光in situハイブリダイゼーション（FISH）などの分子生物学技術の進歩により、分子診断の範囲が拡大しています。これらの技術は、より正確で迅速、かつ非侵襲的な検査の選択肢をもたらし、遺伝子のレベルで病気を検出する能力を高めています。個別化医療は、この成長を促進する重要な要因です。分子診断により、ヘルスケア専門家が個人の遺伝子プロファイルに基づいて治療計画を調整することが可能になり、治療成績が向上し、副作用が最小限に抑えられるからです。

市場は、タイムリーな介入とより良い患者管理を可能にする早期疾患発見の重要性に対する意識の高まりによっても後押しされています。ヘルスケアシステムが予防医療にますます重点を置くようになるにつれて、分子診断薬はがん、糖尿病、心血管疾患などの疾患の日常的なスクリーニングに不可欠なツールになりつつあります。非侵襲的でがんマーカーの検出感度が高いリキッドバイオプシー検査の進歩により、がん領域における分子診断の応用は急速に拡大しています。遺伝子検査は遺伝性疾患の特定や個人の特定疾患のリスク評価に役立つため、遺伝性疾患の有病率の増加も分子診断薬の需要に寄与しています。

有望な成長にもかかわらず、市場はいくつかの課題に直面しています。分子診断検査、特にNGSのような先端技術を用いた検査に関連する高コストは、低資源環境での普及を阻む障壁のままです。また、分子診断の手順が複雑なため、専門的な知識が必要となり、地域によっては利用しにくくなっています。さらに、規制上の課題や分子検査手順の標準化の必要性が市場拡大の妨げとなっています。しかし、技術の進歩によりコストが削減され、検査の精度とアクセシビリティが向上し続けているため、これらの課題は時間の経過とともに緩和されていくと予想されます。民間および公的利害関係者による分子診断薬への投資の増加は、市場成長をさらに後押しし、技術革新のための多くの機会を創出し、これらの重要なヘルスケアツールへのアクセスを拡大すると予想されます。

主な市場促進要因

慢性疾患および遺伝性疾患の有病率の上昇

政府および民間セクターの投資の増加

分子検査技術の進歩

主な市場課題

高度診断検査の高コスト

検査プロトコルの標準化の欠如

主な市場動向

個別化医療とコンパニオン診断

リキッドバイオプシーの利用の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の中核的臨床分子診断市場の展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（機器、試薬とキット、ソフトウェアとサービス）
  • 技術別（PCR、核酸配列、蛍光in situハイブリダイゼーション（FISH）、その他）
  • 用途別（感染症、遺伝性疾患、がん検診、その他）
  • エンドユーザー別（病院および診断研究所、学術調査機関、製薬およびバイオテクノロジー企業、調査受託機関（CRO）、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の中核的臨床分子診断市場の展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • メキシコ
  • カナダ

第7章 欧州の中核的臨床分子診断市場の展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の中核的臨床分子診断市場の展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の中核的臨床分子診断市場の展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの中核的臨床分子診断市場の展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Hologic Inc.
• bioMerieux SA
• Siemens Healthineers AG
• Becton, Dickinson and Company
• Agilent Technologies, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Core Clinical Molecular Diagnostics Market was valued at USD 6.48 Billion in 2024 and is expected to reach USD 11.43 Billion in the forecast period with a CAGR of 9.89% through 2030. The global clinical molecular diagnostics market is witnessing significant growth due to the rising demand for accurate and early detection of various diseases, particularly cancer, infectious diseases, and genetic disorders. Advancements in molecular biology techniques, such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH), are expanding the scope of molecular diagnostics. These technologies have led to more precise, faster, and non-invasive testing options, enhancing the ability to detect diseases at the genetic level. Personalized medicine is a key factor driving this growth, as molecular diagnostics allow healthcare professionals to tailor treatment plans based on individual genetic profiles, improving treatment outcomes and minimizing adverse effects.

The market is also being propelled by the growing awareness of the importance of early disease detection, which enables timely intervention and better patient management. As healthcare systems increasingly focus on preventive care, molecular diagnostics are becoming essential tools in routine screening for conditions like cancer, diabetes, and cardiovascular diseases. The application of molecular diagnostics in oncology is expanding rapidly, with advancements in liquid biopsy tests, which are non-invasive and offer high sensitivity in detecting cancer markers. The growing prevalence of genetic disorders is also contributing to the demand for molecular diagnostics, as genetic testing helps in identifying hereditary conditions and assessing the risk of certain diseases in individuals.

Despite the promising growth, the market faces several challenges. High costs associated with molecular diagnostic tests, particularly those using advanced technologies like NGS, remain a barrier for widespread adoption in low-resource settings. The complexity of molecular diagnostic procedures also requires specialized expertise, which limits accessibility in certain regions. Furthermore, regulatory challenges and the need for standardized procedures for molecular testing hinder market expansion. However, as technological advancements continue to drive down costs and improve the accuracy and accessibility of tests, these challenges are expected to be mitigated over time. The increasing investment in molecular diagnostics by private and public stakeholders is expected to further support market growth, creating numerous opportunities for innovation and expanding access to these critical healthcare tools.

Key Market Drivers

Rising Prevalence of Chronic and Genetic Diseases

The rising prevalence of chronic and genetic diseases significantly drives the global clinical molecular diagnostics market. Chronic diseases, including cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes, are now the leading causes of death worldwide. In 2021, noncommunicable diseases (NCDs) accounted for at least 43 million deaths, representing 75% of all deaths not related to pandemics. Cardiovascular diseases alone were responsible for over 19 million deaths, followed by cancers with 10 million, chronic respiratory diseases with 4 million, and diabetes with over 2 million deaths, including those from kidney disease caused by diabetes.

This escalating burden of chronic diseases underscores the critical need for advanced diagnostic tools capable of early and accurate detection. Molecular diagnostics, such as Polymerase Chain Reaction (PCR) and next-generation sequencing (NGS), offer high sensitivity and specificity, enabling healthcare providers to identify genetic mutations and disease markers at early stages. Early detection is vital for effective management and treatment, potentially reducing healthcare costs and improving patient outcomes.

In addition to chronic diseases, genetic disorders also contribute significantly to the global health burden. It is estimated that approximately 7.9 million births annually, or 6% of total births, occur with a defect of genetic or partially genetic origin. This includes conditions such as hemoglobinopathies (thalassemias and sickle cell diseases), which have high prevalence rates in certain regions.

The increasing recognition of genetic disorders and the demand for personalized medicine further drive the adoption of molecular diagnostics. By identifying specific genetic mutations, these diagnostic tools enable tailored treatment plans, enhancing the effectiveness of interventions and minimizing adverse effects. As the global population ages and lifestyle factors contribute to the rise in chronic diseases, the need for precise and early diagnostic methods becomes more critical, propelling the growth of the molecular diagnostics market.

Increased Government and Private Sector Investment

Increased government and private sector investment plays a pivotal role in propelling the growth of the global core clinical molecular diagnostics market. Governments worldwide are recognizing the critical importance of molecular diagnostics in enhancing healthcare outcomes, managing disease burdens, and advancing public health initiatives. In India, for instance, the government has launched the "Scheme for Promotion of Research and Innovation in Pharma MedTech Sector (PRIP)" with a substantial budget outlay of ₹5,000 crore. This initiative aims to transform the Indian pharmaceutical sector from a cost-based to an innovation-based growth model by strengthening research infrastructure and promoting industry-academia collaborations in priority areas such as new chemical entities, complex generics, medical devices, stem cell therapy, orphan drugs, and antimicrobial resistance.

Private sector investments are equally significant, with companies in the diagnostics, biotechnology, and pharmaceutical sectors dedicating substantial resources to developing and commercializing new molecular diagnostic tests and technologies. For example, the Indian Council of Medical Research (ICMR) provides financial assistance to Indian scientists working outside its institutes to conduct research in medicine and public health, thereby fostering innovation and facilitating the adoption of these tools in clinical settings.

These investments not only expedite the development of advanced diagnostic tools but also play a crucial role in scaling production, enhancing test accuracy, and reducing costs, making molecular diagnostics more accessible and affordable for healthcare providers and patients. The collaboration between private companies and academic institutions accelerates the pace of innovation by leveraging the strengths of both entities, leading to the creation of integrated solutions that combine diagnostics with targeted treatments. As these investments continue to flow into the sector, the clinical molecular diagnostics market is poised for sustained growth, with improved diagnostic tools becoming more accessible to patients worldwide.

Technological Advancements in Molecular Testing

Technological advancements in molecular testing are a primary driver of growth in the global clinical molecular diagnostics market. Recent innovations have significantly improved the accuracy, speed, and accessibility of diagnostic tests, transforming the healthcare landscape. The development of high-throughput sequencing technologies, such as next-generation sequencing (NGS), allows for the simultaneous analysis of multiple genes, mutations, and biomarkers, providing a more comprehensive view of a patient's genetic profile. This has been particularly transformative in oncology, where NGS enables the identification of genetic mutations and tumor profiles, facilitating the selection of targeted therapies tailored to individual patients. These advancements are also expanding the role of molecular diagnostics in areas such as infectious disease detection and genetic disorder screening, where precision is critical for effective treatment and management.

Advancements in PCR (Polymerase Chain Reaction) technology have further contributed to the growth of the market. PCR-based assays, particularly real-time PCR, are now faster and more sensitive, enabling accurate detection of pathogens and genetic abnormalities at early stages. The miniaturization of PCR devices has led to the development of point-of-care testing solutions that allow for rapid, on-site diagnostic results, which is particularly valuable in emergency or remote healthcare settings. Innovations in multiplex testing, which allow for the simultaneous detection of multiple pathogens or genetic markers in a single test, are also driving the market by improving efficiency and reducing the need for multiple diagnostic procedures.

The integration of artificial intelligence (AI) and machine learning (ML) in molecular diagnostics is enhancing data analysis capabilities, allowing for faster and more accurate interpretation of test results. AI-driven algorithms are increasingly being used to analyze complex genomic data, improving diagnostic precision and supporting more personalized treatment plans. These technological advancements are making molecular diagnostics more accessible, efficient, and indispensable in modern healthcare.

Key Market Challenges

High Cost of Advanced Diagnostic Tests

The high cost of advanced diagnostic tests presents a significant challenge for the global clinical molecular diagnostics market. These tests, particularly those involving next-generation sequencing (NGS), polymerase chain reaction (PCR), and other sophisticated technologies, often require specialized equipment, reagents, and technical expertise. The development, production, and maintenance of such equipment can be expensive, leading to higher prices for diagnostic tests. Additionally, these tests often involve multiple steps, such as sample preparation, analysis, and interpretation, which require skilled personnel and advanced laboratory infrastructure. For healthcare providers, the financial burden of acquiring and maintaining these technologies can be considerable, especially in resource-constrained settings.

In India, the Economic Survey 2017-2018 highlighted the arbitrary pricing and wide differences in rates of diagnostic tests across cities, stressing the need for regularizing the sector. For example, the minimum rate charged for a Lipid Profile test was Rs 90, while the maximum was Rs 7,110 in several cities. Similarly, some diagnostic centers charged Rs 100 for a Thyroid Test, while others charged Rs 3,100 for the same test.

The high cost is a barrier to the accessibility of molecular diagnostics in many regions, particularly in developing countries. In these markets, healthcare systems often struggle to justify the investment in costly molecular diagnostic equipment and reagents when more affordable traditional diagnostic methods are available. This leads to disparities in the availability of advanced molecular diagnostic tests, limiting their potential to improve patient outcomes in underserved populations. Moreover, the expense of these tests can result in patients facing out-of-pocket costs that may be unaffordable, particularly when insurance coverage is limited or reimbursement rates are low.

In response to these challenges, the Government of India launched the Free Diagnostics Service Initiative under the National Health Mission. This initiative aims to provide accessible and affordable pathological and radiological diagnostic services closer to the community, thereby reducing out-of-pocket expenditure. The program offers a minimum set of essential diagnostic tests at each level of public health facility, with guidelines shared with all states and union territories.

In addition to the initial high cost of diagnostic tests, the ongoing operational costs of maintaining molecular diagnostic technologies, such as regular maintenance, calibration, and training of personnel, contribute to the financial strain. The complexity of molecular diagnostics further exacerbates the challenge, as errors in testing or interpretation can lead to additional costs related to retesting or misdiagnoses. As a result, addressing the high cost of advanced diagnostic tests is crucial for improving the accessibility and affordability of molecular diagnostics globally, particularly as the demand for precision medicine and personalized healthcare continues to rise.

Lack of Standardization in Testing Protocols

A significant challenge faced by the global clinical molecular diagnostics market is the lack of standardization in testing protocols. Molecular diagnostic tests, which rely on advanced technologies like PCR, next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH), vary widely in their methods, procedures, and interpretations across different regions and healthcare settings. The absence of universally accepted testing protocols creates inconsistencies in results, leading to potential discrepancies in patient diagnosis and treatment decisions. These variations can occur due to differences in reagent quality, sample preparation methods, and equipment used across different laboratories, which may affect test accuracy and reproducibility.

The lack of standardization also complicates the validation and comparison of diagnostic tests across clinical environments, making it difficult for healthcare professionals to assess the reliability and performance of different diagnostic tools. Without uniform testing protocols, laboratories may use different thresholds or cut-off points when interpreting results, which can lead to misinterpretations or unnecessary treatments. This issue is particularly problematic when dealing with complex diseases like cancer or genetic disorders, where molecular diagnostics are critical for treatment decisions. As a result, clinicians and patients may face uncertainty regarding the test's reliability or its suitability for specific clinical applications.

This lack of consistency also hinders the widespread adoption of molecular diagnostics, especially in emerging markets. Laboratories in low-resource settings may lack the infrastructure or expertise to implement the same level of testing standards found in well-established healthcare systems. The absence of globally accepted guidelines and regulatory frameworks further exacerbates the problem, delaying the introduction of new diagnostic innovations and creating barriers to market access. Standardizing testing protocols would help address these issues, ensuring better diagnostic accuracy, reliability, and broader adoption of molecular diagnostics across healthcare systems worldwide.

Key Market Trends

Personalized Medicine and Companion Diagnostics

Personalized medicine and companion diagnostics are driving significant transformation in the global clinical molecular diagnostics market by enabling more tailored healthcare solutions based on an individual's genetic makeup. Personalized medicine involves customizing treatments to individual patients, utilizing molecular diagnostic tools to identify genetic variations, mutations, and biomarkers that influence disease progression and treatment response. These advancements are leading to more precise diagnoses and treatment regimens, minimizing side effects and enhancing therapeutic outcomes.

A critical component of personalized medicine is companion diagnostics, which are tests used alongside specific therapies to identify which patients will benefit from a particular treatment. Companion diagnostics help ensure that patients receive therapies targeted to their genetic profiles, especially in oncology, where treatments like targeted therapies and immunotherapies require genetic or biomarker testing to identify the most appropriate candidates. For instance, in 2022, the U.S. FDA approved multiple companion diagnostics for oncology, such as tests identifying tumors with HER2 mutations, further supporting the expansion of personalized treatment approaches.

The global personalized medicine market is expected to see continued growth, with key advancements in next-generation sequencing (NGS) technologies driving precision diagnostics. The U.S. FDA's increasing focus on companion diagnostics, including those used for genetic-based treatments in cancer and rare diseases, reflects a broader shift toward precision healthcare. Governments worldwide are supporting this shift with funding for research and development initiatives aimed at enhancing genomic medicine capabilities. For example, in 2022, the U.S. National Cancer Institute allocated substantial funds to promote the integration of telehealth and genomic medicine, particularly to improve cancer care access. The increasing adoption of NGS and genetic testing platforms, along with the growing understanding of the human genome, is expected to further fuel the expansion of personalized medicine. As a result, companion diagnostics will continue to play a crucial role in optimizing patient care, ensuring that treatments are more effective and individualized.

Increased Use of Liquid Biopsy

The increased use of liquid biopsy is becoming a prominent trend in the global core clinical molecular diagnostics market. Liquid biopsy is a non-invasive diagnostic method that analyzes bodily fluids such as blood, urine, or saliva to detect genetic mutations, tumor markers, or other molecular characteristics associated with various diseases, particularly cancer. Unlike traditional biopsy, which requires tissue samples obtained through invasive procedures, liquid biopsy allows for continuous, real-time monitoring of disease progression, treatment response, and the detection of recurrences without the need for further invasive testing. This ability to detect molecular changes from a simple blood draw offers significant advantages in clinical settings, especially for patients who may be difficult to biopsy due to tumor location or other factors.

In oncology, liquid biopsy is gaining significant traction for early cancer detection, monitoring tumor dynamics, and guiding personalized treatment. By detecting tumor DNA, RNA, or exosomes in circulating blood, it provides valuable insights into the genetic makeup of tumors, including mutations, copy number variations, and genetic fusions, which are critical for selecting targeted therapies and immunotherapies. Liquid biopsy can also be used to assess minimal residual disease, monitor treatment efficacy, and detect resistance mutations, enabling clinicians to make timely adjustments to treatment regimens. This non-invasive approach significantly enhances the patient experience by reducing the need for repeated and painful tissue biopsies.

As research and technology continue to advance, the sensitivity and specificity of liquid biopsy tests are improving, expanding their use beyond oncology to other areas like genetic disorders, infectious diseases, and prenatal testing. The growing adoption of liquid biopsy is transforming the diagnostic landscape, providing a more accessible, cost-effective, and patient-friendly alternative to traditional biopsy methods.

Segmental Insights

Product Type Insights

Based on the Product Type, Reagents & Kits emerged as the dominant segment in the Global Core Clinical Molecular Diagnostics Market in 2024. This is due to their essential role in enabling molecular diagnostic tests. These products are critical components in the diagnostic workflow, providing the necessary tools for DNA or RNA extraction, amplification, and analysis in various diagnostic applications, such as PCR, nucleic acid sequencing, and genetic testing. Reagents and kits offer standardization and convenience, ensuring consistent and reliable results, which are essential in clinical diagnostics. The increasing demand for molecular diagnostics across various disease areas, including cancer, infectious diseases, and genetic disorders, has driven the growth of reagents and kits. As healthcare providers adopt advanced molecular diagnostic techniques, the need for high-quality, pre-packaged reagents and kits that simplify testing procedures and reduce time-to-result has surged. Furthermore, these products are widely used in both clinical and research settings, contributing to their large market share. The continuous advancements in molecular testing technologies and the growing trend towards personalized medicine, which requires precise and targeted diagnostic tools, further boost the demand for reagents and kits. This segment's growth is supported by the need for efficient and scalable diagnostic solutions in an increasingly complex healthcare environment.

Application Insights

Based on the Application, Infectious Disease emerged as the dominant segment in the Global Core Clinical Molecular Diagnostics Market in 2024. This is due to the increasing prevalence of infectious diseases and the growing need for rapid, accurate diagnostic solutions. Molecular diagnostic techniques, such as PCR and nucleic acid sequencing, offer high sensitivity and specificity for detecting pathogens at the genetic level, enabling the early detection and precise identification of various infections, including viral, bacterial, and fungal diseases. This capability is crucial for timely treatment, containment, and reducing the spread of infectious diseases. The rising global burden of infectious diseases, including COVID-19, HIV, tuberculosis, and other emerging pathogens, has significantly driven the demand for molecular diagnostics in this application area. With the need for quicker results and more accurate pathogen identification, molecular methods outperform traditional diagnostic techniques like cultures and antigen tests, which can be slower and less reliable. The ability to detect multiple pathogens simultaneously through multiplex PCR testing and the growing trend of point-of-care molecular diagnostics further contribute to the dominance of this segment. In addition, governments and healthcare systems are increasingly investing in molecular diagnostic infrastructure for better management of infectious disease outbreaks, supporting the expansion of the infectious disease application segment.

Regional Insights

North America emerged as the dominant region in the Global Core Clinical Molecular Diagnostics Market in 2024. This is due to a combination of factors, including advanced healthcare infrastructure, high healthcare expenditure, and strong demand for innovative diagnostic technologies. The region, particularly the United States, is home to leading diagnostic companies and research institutions, driving continuous innovation in molecular diagnostics. This environment fosters the rapid adoption of cutting-edge technologies such as next-generation sequencing (NGS), PCR, and liquid biopsy, which are increasingly being utilized for personalized medicine, oncology, infectious diseases, and genetic testing. Furthermore, North America has well-established regulatory frameworks, such as those enforced by the U.S. Food and Drug Administration (FDA), which ensures the quality and safety of molecular diagnostic products, increasing trust and confidence in these tests. The region's healthcare systems are also highly developed, providing greater accessibility to advanced diagnostic tools across both urban and rural areas. Additionally, the growing emphasis on precision medicine, coupled with significant investments in research and development, has accelerated the adoption of molecular diagnostics in North America. The presence of a large number of academic and clinical research collaborations further supports the region's leadership in advancing diagnostic technologies, making it a key player in the global market.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Hologic Inc.
• bioMerieux SA
• Siemens Healthineers AG
• Becton, Dickinson and Company
• Agilent Technologies, Inc.

Report Scope:

In this report, the Global Core Clinical Molecular Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Core Clinical Molecular Diagnostics Market, By Product Type:

• Instruments
• Reagents & Kits
• Software & Services

Core Clinical Molecular Diagnostics Market, By Technology:

• PCR
• Nucleic Acid Sequencing
• Fluorescence In Situ Hybridization (FISH)
• Others

Core Clinical Molecular Diagnostics Market, By Application:

• Infectious Disease
• Genetic Disorder
• Cancer Screening
• Others

Core Clinical Molecular Diagnostics Market, By End User:

• Hospitals & Diagnostic Laboratories
• Academic & Research Institutions
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Others

Core Clinical Molecular Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Core Clinical Molecular Diagnostics Market.

Available Customizations:

Global Core Clinical Molecular Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Core Clinical Molecular Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Instruments, Reagents & Kits, Software & Services)
  • 5.2.2. By Technology (PCR, Nucleic Acid Sequencing, Fluorescence In Situ Hybridization (FISH), Others)
  • 5.2.3. By Application (Infectious Disease, Genetic Disorder, Cancer Screening, Others)
  • 5.2.4. By End User (Hospitals & Diagnostic Laboratories, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Core Clinical Molecular Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Core Clinical Molecular Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Core Clinical Molecular Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Core Clinical Molecular Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Core Clinical Molecular Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Core Clinical Molecular Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Core Clinical Molecular Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Core Clinical Molecular Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Core Clinical Molecular Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Core Clinical Molecular Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Core Clinical Molecular Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Core Clinical Molecular Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Core Clinical Molecular Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Core Clinical Molecular Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Core Clinical Molecular Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Core Clinical Molecular Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Core Clinical Molecular Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Core Clinical Molecular Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Core Clinical Molecular Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Core Clinical Molecular Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Core Clinical Molecular Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Core Clinical Molecular Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Core Clinical Molecular Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Core Clinical Molecular Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Danaher Corporation
• 14.3. Abbott Laboratories
• 14.4. Thermo Fisher Scientific Inc.
• 14.5. QIAGEN N.V.
• 14.6. Hologic Inc.
• 14.7. bioMerieux SA
• 14.8. Siemens Healthineers AG
• 14.9. Becton, Dickinson and Company
• 14.10. Agilent Technologies, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer